Celebrex TV Ad Focuses On Joint Pain Relief
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer's direct-to-consumer campaign advertises that Celebrex "targets the source of pain and inflammation" but does not "slow you down." The COX-2 inhibitor has received increased scrutiny following the Vioxx withdrawal.
You may also be interested in...
Celebrex New Year's Resolution Is Final Spot Before DTC Hibernation
The ad ran in the Dec. 19 New York Times Magazine, the day before FDA announced that Pfizer had agreed to halt DTC ads. The ad features cartoon characters making snow angels under the statement "Arthritis pain? Bah, Humbug!"
Celebrex New Year's Resolution Is Final Spot Before DTC Hibernation
The ad ran in the Dec. 19 New York Times Magazine, the day before FDA announced that Pfizer had agreed to halt DTC ads. The ad features cartoon characters making snow angels under the statement "Arthritis pain? Bah, Humbug!"
Celebrex Database Clear Of Cardiovascular Signals, FDA’s Woodcock Says
Data safety monitoring boards for ongoing prevention trials with Pfizer’s Celebrex say there is no indication the trials should be stopped. However, FDA is hesitant to make a final determination on Celebrex safety. The safety profile for Pfizer’s Bextra also is inconclusive, Woodcock says.